RARE Ultragenyx Pharmaceutical Inc. stock chart & analysis
Conviction 45HealthcareScan · Fri, Nov 6, 2026Ultragenyx Pharmaceutical Inc. (RARE) closed at $15.43 (-0.90%) on Nov 6, 2026. Price is below its 50-day and below its 200-day moving average. RSI(14) 45, RS Rating 10, -61.3% from its 52-week high, -32.9% year to date. Sector: Healthcare · Pharmaceutical Preparations.
Financials as of Wed, Sep 30, 2026 · quarterly.
RARE technical analysis
Trend
RARE is in a downtrend: price is below the 50-day, which is below the 200-day moving average. It closed 3.7% below the 50-day ($16.02) and 32.1% below the 200-day ($22.73). ADX(14) at 16 points to a weak trend — more range than direction. It meets 1 of 8 trend-template criteria.
Momentum
RSI(14) is 45, in the bearish half of its range. The MACD histogram is positive. Its RS Rating of 10 puts its weighted 12-month performance ahead of about 10% of the US market.
Volume and volatility
Volume on the latest session ran 1.3× its 20-day average. It trades about $57.7M a day on average. ATR(14) is $0.9165, 5.9% of price — its typical daily range.
Key levels
The chart pattern's support is $13.41 and its resistance $17.65. The 52-week range is $12.73 to $39.89; price is 61.3% below the high and 21.2% above the low. The VWAP anchored at the 52-week high is $21.57, above price.
Performance
RARE returned -4.2% (1 week), +0.9% (1 month), -42.4% (3 months), -40.9% (6 months), -51.6% (1 year), -32.9% (year to date).
About Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic conditions. Its medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged one year and older. Mepsevii is indicated for pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. The company operates across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific, with the majority of its revenue generated from North America.
Pharmaceutical Preparations · Listed 2014 · 1,371 employees
Signal lifecycle
How this symbol has moved through the lanes across 60 scans — each scan is re-classified from that day's price, so gaps are days it dropped off the board entirely.
- Setting upOct 23 – Oct 262 scans
- Breaking out nowOct 271 scan
Congress activity
Disclosed STOCK Act trades in RARE · 4 recent
| Member | Side | Amount | Traded | Filed | PTR |
|---|---|---|---|---|---|
 Gilbert Cisneros house · D · CA · traded 2026-09-29 | Buy | $1K–$15K | 2026-09-29 | 2026-10-12 | |
Gilbert Cisneros house · CA · traded 2026-03-03 | Buy | $1K–$15K | 2026-03-03 | 2026-04-06 | |
Gilbert Cisneros house · D · CA · traded 2025-08-08 | Buy | $1K–$15K | 2025-08-08 | 2025-09-12 | |
Gilbert Cisneros house · D · CA · traded 2025-07-15 | Buy | $1K–$15K | 2025-07-15 | 2025-08-14 |
Insider activity
SEC Form 4 transactions in RARE · open-market 4 sells
| Insider | Side | Shares | Value | Traded | Filed |
|---|---|---|---|---|---|
Horn Howard Chief Financial Officer · Common Stock · 2026-10-15 | Sell | 7.07K | $108K | 2026-10-15 | 2026-10-19 |
Huizenga Theodore Alan SVP, Chief Accounting Officer · Common Stock · 2026-09-15 | Sell | 1.28K | $17K | 2026-09-15 | 2026-09-15 |
Horn Howard Chief Financial Officer · Common Stock · 2026-06-01 | Sell | 4.65K | $111K | 2026-06-01 | 2026-06-01 |
SULIMAN SHEHNAAZ Director · Common Stock · 2026-05-18 | Sell | 5.74K | $144K | 2026-05-18 | 2026-05-18 |
Sanders Corazon (Corsee) D. Director · Common Stock · 2026-05-14 | Grant | 7.75K | $0 | 2026-05-14 | 2026-05-18 |
Fust Matthew K Director · Stock Option (Right to Buy) · 2026-05-14 | Grant | 14.06K | $0 | 2026-05-14 | 2026-05-18 |
Ray Amrit Director · Common Stock · 2026-05-14 | Grant | 7.75K | $0 | 2026-05-14 | 2026-05-18 |
Fust Matthew K Director · Common Stock · 2026-05-14 | Grant | 7.75K | $0 | 2026-05-14 | 2026-05-18 |
Ray Amrit Director · Stock Option (Right to Buy) · 2026-05-14 | Grant | 14.06K | $0 | 2026-05-14 | 2026-05-18 |
WELCH DANIEL G Director · Stock Option (Right to Buy) · 2026-05-14 | Grant | 14.06K | $0 | 2026-05-14 | 2026-05-18 |
SEC filings
EDGAR filings in RARE · 10 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, no credit card.
Start free — 7-day trial, no card →Free daily signals by email. Top 3 setups per lane after every close. No account needed.
Unsubscribe anytime · Privacy
Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.